Cordis promotes Alan Tsai as GM Greater China
SHANGHAI, Nov. 7, 2022 /PRNewswire/ -- From November 1, 2022, Mr. Alan Tsai is promoted to the role of General Manager of Cordis Greater China. He will head the leadership team responsible for strategic planning, business operation and team development for Greater China, the fastest growing area in Asia Pacific. Based in Shanghai, he will report directly to Bryan...
HMA partners Baxter to deliver webinar series on patient care challenges and innovations
Series of educational webinars will bring together C-suite speakers from top hospitals in Asia, covering topics from burnout to healthcare-associated infections Vietnam, Nov. 7, 2022 /PRNewswire/ -- Asia's hospital administrations and healthcare executives are grappling with challenges evolving on multiple fronts. While patient volumes climb, healthcare staff shortages are becoming more acute. At the same time, the need to...
Preliminary Results from Two Clinical Studies of Selinexor to be Presented at 2022 ASH Annual Meeting
- Poster with updated Phase Ib TOUCH results suggest selinexor plus GemOx could provide a therapeutic option for heavily pre-treated Stage III/IV patients with relapsed/refractory (R/R) T and NK-cell lymphoma- Online abstract with results from the open-label LAUNCH study demonstrated the encouraging efficacy of selinexor in combination with dexamethasone and chemotherapy in...
EMA Aesthetics signs agreement with 4ocean to become ‘plastics neutral’.
DUBLIN, Nov. 7, 2022 /PRNewswire/ -- EMA Aesthetics (www.emaaesthetics.com), an international aesthetics company headquartered in Dublin, announces its collaboration with 4ocean, the ocean cleanup company that's on a mission to end the world's ocean plastic crisis. The goal of EMA Aesthetics participation in 4ocean's Certified Cleanup Partnership Program is to become plastics neutral across...
Hexvix®, A Diagnostic Drug for Bladder Cancer of Asieris, Completed the First Patient Dose in Phase III Trial
SHANGHAI, Nov. 7, 2022 /PRNewswire/ -- Asieris Pharmaceuticals, a global biopharmaceutical company specializing in the discovery and development of innovative drugs for the treatment of genitourinary tumors and other major diseases, announced that Hexvix®, a drug used for the diagnosis for bladder cancer, completed the first patient dose in Phase III bridging trial. The study is a prospective, self-controlled,...
Ascletis Announces Poster Presentation of Phase I, Single-Dose Study of ASC43F for NASH at AASLD Annual Meeting 2022
HANGZHOU and SHAOXING, China, Nov. 7, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces today that the abstract of a Phase I, Single-Dose Study of ASC43F for non-alcoholic steatohepatitis (NASH) has been reported at The Liver Meeting® 2022 of the American Association for the Study of Liver Diseases (AASLD) as poster presentation. The summary of the abstract is...
Innovent Releases Results of a Phase 3 Clinical Study of Tafolecimab（IBI306）in Chinese Patients with non- Familial Hypercholesterolemia at the American Heart Association (AHA) Scirntific Sessions 2022
ROCKVILLE, M.D. and SUZHOU, China, Nov 7, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces that the results of a phase 3 clinical study (CREDIT-1) of tafolecimab (IBI306), a recombinant fully human anti-PCSK-9 monoclonal antibody,...
Herbalife Nutrition Survey: Unbalanced Diet, Physical Inactivity and Inadequate Sleep Among the Top Unhealthy Habits APAC Consumers Want to Kick in Next 12 Months
Virtual Run by Herbalife Nutrition is back for the third year running to spur actions for building healthy active living habits among Asia Pacific consumers SYDNEY, Nov. 7, 2022 /PRNewswire/ -- Premier global nutrition company, Herbalife Nutrition released the findings from its Asia Pacific Personal Habits Survey today, revealing that 8 out of ten consumers in the APAC region...
Brexogen’s Exosome Therapy for Atopic Dermatitis, ‘BRE-AD01’ Accepted for Phase 1 Clinical Trials by US FDA
First entry to clinical trial of exosome for atopic dermatitis The first exosome-based therapeutics in US clinical trial among Korean companies SEOUL, South Korea, Nov. 7, 2022 /PRNewswire/ -- The US FDA granted the initiation of the phase 1 clinical trial of 'BRE-AD01', an exosome- based therapy for atopic dermatitis. 'BRE-AD01'...
Telix Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study
Summary of Study Outcomes ZIRCON Phase III study of Telix's investigational imaging agent TLX250-CDx in clear cell renal cell carcinoma (ccRCC) has met all of its primary and secondary endpoints The study delivered co-primary endpoints of 86% sensitivity and 87% specificity and 93% positive predictive value (secondary endpoint) considerably exceeding sensitivity...
